DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE
18 Março 2021 - 9:30AM
Daxor Corporation (NYSE: DXR), the global leader in blood volume
measurement technology, announces today that President and CEO
Michael Feldschuh will participate in the Benzinga Biotech Small
Cap Conference to be held March 24th to 25th, 2021. Mr. Feldschuh
will present on March 24th at 12:30 PM EDT.
Mr. Feldschuh will provide an overview on the
Company’s business model and growth strategy, including updates on
ground-breaking research and product development, contracts with
the US Department of Defense, grant funding through the National
Institute of Health, and new prospective medical trials using Daxor
BVA-100® blood test in the management of critical care, COVID-19,
and heart failure.
Investors can view Mr. Feldschuh’s general
corporate presentation once they register for the conference, and
an archived replay of the presentation will be available via the
conference website. Investors can also request a one-on-one meeting
with Mr. Feldschuh following the conclusion of the conference.
Event: Benzinga Biotech Small Cap
ConferenceDate: March 24th, 2021 at 12:30 PM EDTRegister here.
Interested investors can contact Bret Shapiro at
COREIR either by calling 1-516-222-2560 or emailing
brets@coreir.com.
About Daxor CorporationDaxor
Corporation (NYSE: DXR) is the global leader in blood volume
measurement technology focused on blood volume testing innovation
(organized as an investment company with fully-owned innovative
medical instrumentation and biotechnology operations). We developed
and market the BVA-100® (Blood Volume Analyzer), the first
diagnostic blood test cleared by the FDA to provide safe, accurate,
objective quantification of blood volume status and composition
compared to patient-specific norms. The BVA technology enhances
hospital performance metrics in a broad range of surgical and
medical conditions, including heart failure and critical care, by
informing treatment strategies, resulting in significantly improved
multiple measures of patient outcomes. Daxor's mission is to
advance healthcare by enabling optimal fluid management with blood
volume analysis. Daxor’s vision is optimal blood volume for all.
For more information, please visit our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024